GS-441524

Catalog No.S6814 Batch:S681403

Print

Technical Data

Formula

C12H13N5O4
Molecular Weight 291.26 CAS No. 1191237-69-0
Solubility (25°C)* In vitro DMSO 58 mg/mL (199.13 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
2.9mg/ml Taking the 1 mL working solution as an example, add 50 μL of 58 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.725mg/ml Taking the 1 mL working solution as an example, add 50 μL of 14.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description GS-441524, a molecular precursor to a pharmacologically active nucleoside triphosphate molecule, is a potent inhibitor of feline infectious peritonitis virus (FIPV) with EC50 of 0.78 μM.
Targets
FIPV [1]
(Cell-free assay)
0.78 μM(EC50)

Protocol (from reference)

Selleck's GS-441524 has been cited by 7 publications

Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient [ Infect Drug Resist, 2024, 17:531-541] PubMed: 38348230
Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction [ Commun Biol, 2023, 6(1):511] PubMed: 37173432
Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats [ EBioMedicine, 2022, 81:104095] PubMed: 35671622
Comparative bioavailability study following a single dose intravenous and buccal administration of remdesivir in rabbits [ Int J Pharm, 2022, 620:121739] PubMed: 35421532
Predicting In Vitro and In Vivo Anti-SARS-CoV-2 Activities of Antivirals by Intracellular Bioavailability and Biochemical Activity [ ACS Omega, 2022, 7(49):45023-45035] PubMed: 36530252
Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker® [ Toxicol Lett, 2022, 362:50-58] PubMed: 35569722
Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives [ Front Pharmacol, 2020, 11:606097] PubMed: 33519469

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.